ArticleCancer immunology, immunotherapy : CII2021
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02937116 (An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors.Frontiers in pharmacology · 2023Pooled it
- Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial.Cell reports. Medicine · 2025Trial
- Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).Cancer communications (London, England) · 2022Trial
- Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function.Pakistan journal of medical sciences · 2026Article
- Hsa_circ_0125356 promotes gemcitabine resistance by modulating WNT canonical and non-canonical pathways via miR-582-5p/FGF9 axis in non-small cell lung cancer.Molecular cancer · 2025Article
- Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies.Frontiers in oncology · 2025Article
- Insights into cytomegalovirus-associated T cell receptors in recipients following allogeneic hematopoietic stem cell transplantation.Virology journal · 2024Article
- The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer.Cancer medicine · 2024Review
- T-cell receptor and B-cell receptor repertoires profiling in pleural tuberculosis.Frontiers in immunology · 2024Article
- Sintilimab Combined with Nanoparticle Albumin-Bound Paclitaxel-Based Chemotherapy in Severe Locally Advanced or Metastatic Squamous NSCLC Showed Good Efficacy and Safety: A Pilot Retrospective Analysis.International journal of nanomedicine · 2024Article
- Potential biomarkers for immunotherapy in non-small-cell lung cancer.Cancer metastasis reviews · 2023Review
- Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses.Heliyon · 2023Review
- Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer.Discover oncology · 2022Article
- Sintilimab for the treatment of non-small cell lung cancer.Biomarker research · 2022Review
- Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.Translational cancer research · 2022Article
- [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Article
- A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study).Annals of translational medicine · 2021Article
- Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.Cancer medicine · 2021Article
- Research progress in immune checkpoint inhibitors for lung cancer in China.Therapeutic advances in medical oncology · 2021Review
- Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
Combining chemotherapy with immunotherapy improves the therapeutic outcome for first-line (1L) patients with advance nonsmall-cell lung cancer (NSCLC). Two cohorts of a phase 1b study (NCT02937116) aimed to evaluate the safety and efficacy of sintilimab, a PD-1 inhibitor, plus chemotherapy in 1L patients with nonsquamous and squamous NSCLC (nsqNSCLC/sqNSCLC); and to identify potential biomarkers for treatment response. Treatment-naïve patients with nsqNSCLC were enrolled and intravenously given sintilimab (200 mg), pemetrexed (500 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.